Merck & Co., Inc. Stock price

Equities

MRK

US58933Y1055

Pharmaceuticals

Market Closed - Nyse 21:00:01 23/02/2024 GMT 5-day change 1st Jan Change
129.4 USD +0.15% Intraday chart for Merck & Co., Inc. +1.30% +18.74%
Sales 2023 60.12B 4,746B Sales 2024 * 63.59B 5,020B Capitalization 328B 25,897B
Net income 2023 365M 28.82B Net income 2024 * 19.67B 1,553B EV / Sales 2023 4.6 x
Net Debt 2023 * 28.54B 2,253B Net Debt 2024 * 19.43B 1,534B EV / Sales 2024 * 5.46 x
P/E ratio 2023
779 x
P/E ratio 2024 *
16.5 x
Employees 68,000
Yield 2023 *
2.24%
Yield 2024 *
2.4%
Free-Float 70.8%
More Fundamentals * Assessed data
Dynamic Chart
Merck Says EMA Committee Endorses Keytruda Combination for Resectable Lung Cancer MT
Merck's Lung Cancer Therapy Receives Positive Opinion for EU Approval MT
Merck: positive CHMP opinion for Keytruda in NSCLC CF
Merck Gets CHMP Backing for Keytruda in Certain Non-Small Cell Lung Cancer DJ
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for the Treatment of Resectable NSCLC at High Risk of Recurrence CI
Weight-loss drugs could boost US GDP by 1% in coming years, Goldman says RE
Merck's Keytruda Gets FDA's Priority Review for Endometrial Carcinoma MT
Merck: priority review in endometrial cancer. CF
Merck Gets Speedy FDA Review for New Keytruda Uterine Cancer Indication DJ
FDA Grants Priority Review to Merck's Application for Keytruda (Pembrolizumab) Plus Chemotherapy as Treatment for Primary Advanced or Recurrent Endometrial Carcinoma CI
Merck & Co. Insider Sold Shares Worth $29,538,998, According to a Recent SEC Filing MT
Merck & Co. Insider Sold Shares Worth $4,805,521, According to a Recent SEC Filing MT
Soros Fund Management Llc Dissolves Share Stake In General Motors, Apple, Maplebear; Takes Share Stake In Merck RE
Putin says Russia is close to creating cancer vaccines RE
Merck & Co. Insider Sold Shares Worth $1,845,083, According to a Recent SEC Filing MT
More news
1 day+0.15%
1 week+1.30%
Current month+7.18%
1 month+8.02%
3 months+27.31%
6 months+16.31%
Current year+18.74%
More quotes
1 week
126.80
Extreme 126.8
130.24
1 month
118.66
Extreme 118.66
130.24
Current year
109.16
Extreme 109.16
130.24
1 year
99.14
Extreme 99.14
130.24
3 years
70.89
Extreme 70.89
130.24
5 years
65.25
Extreme 65.25
130.24
10 years
45.69
Extreme 45.69
130.24
More quotes
Managers TitleAgeSince
Chief Executive Officer 57 31/03/14
Director of Finance/CFO 55 31/12/89
Compliance Officer 42 31/01/18
Members of the board TitleAgeSince
Director/Board Member 63 26/11/07
Director/Board Member 66 31/08/15
Director/Board Member 69 28/02/18
More insiders
Date Price Change Volume
23/02/24 129.4 +0.15% 5,177,378
22/02/24 129.3 +0.89% 6,517,381
21/02/24 128.1 +0.59% 4,849,322
20/02/24 127.4 -0.33% 6,952,764
16/02/24 127.8 +0.99% 6,266,778

Delayed Quote Nyse, February 23, 2024 at 09:00 pm

More quotes
Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows: - sale of pharmaceutical products (69.7%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.; - sale of vaccines (18%); - sale of animal health products (9.4%); - other (2.9%). Net sales are distributed geographically as follows: the United States (45.9%), Europe/Middle East/Africa (24.5%), China (8.8%), Japan (6.1%), Asia/Pacific (6.1%), Latin America (4.3%) and other (4.3%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
27
Last Close Price
129.4 USD
Average target price
133.6 USD
Spread / Average Target
+3.24%
Consensus
1st Jan change Capi.
+18.74% 328 B $
+32.01% 693 B $
+21.62% 550 B $
+3.25% 390 B $
+14.92% 315 B $
+7.97% 213 B $
-4.95% 212 B $
-3.58% 201 B $
-3.58% 157 B $
+0.42% 155 B $
Other Pharmaceuticals
  1. Stock
  2. Equities
  3. Stock Merck & Co., Inc. - Nyse
+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019
Replicate our performance
fermer